Hypercalcemia is rarely seen in childhood malignancies and the incidence has been reported to range from 0.4 to 1.3%.
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The most common malignancies associated with hypercalcemia include AML and lymphoma, and solid tumors such as rhabdomyosarcoma and neuroblastoma. Among the hematological malignancies, hypercalcemia is an extremely rare complication of ALL. 2 We report on an 18-year-old male BMT recipient who presented with profound hypercalcemia and bone pain that preceded relapse of monosomy 7-positive AML by 3 weeks.
An 18-year-old man presented with low back and left knee pain 38 days after a matched sibling allogeneic BMT for multiply relapsed monosomy 7-positive AML. Following transplant, he demonstrated no signs or symptoms of GVHD and remained on cyclosporine for GVHD prophylaxis. Within 48 h of admission, his left knee had become markedly swollen and painful. Initial laboratory evaluation revealed an elevated serum calcium level of 13.4 mg per 100 mL that later peaked at 16.2 mg per 100 mL. The serum phosphate level was also elevated at 6.6 mg per 100 mL. A complete blood count showed a WBC count of 3900 Â 10 3 /mm 3 with no blasts, hemoglobin concentration of 8.4 g per 100 mL and platelet count of 30 000/mL. BM testing revealed significant fibrosis and o5% blasts, inconsistent with a diagnosis of relapse. Flow cytometry performed on marrow blood demonstrated only a small myeloblast population (1.4% of the total number of cells) that was positive for CD13, CD33, CD34, CD45 and HLA-DR.
Although radiographs and magnetic resonance imaging showed no bony lesions, a bone scan showed diffuse skeletal uptake that was more pronounced in the periarticular areas of the shoulders, knees and feet. Additional investigations for the etiology of hypercalcemia revealed normal levels of serum parathyroid hormone (PTH) (19 pg/mL, normal 9-73 pg/mL), PTH-related peptide (o1.9 pmol/L) and 25-(OH) vitamin D (22 ng/mL, normal 20-100 ng/mL) with low 1,25-(OH) 2 vitamin D (o8 pg/mL). Treatment was started with calcitonin and pamidronate (1.5 mg/kg i.v) and the serum calcium subsequently normalized within 72 h. A rheumatology workup revealed significantly elevated C-reactive protein levels (23.2 mg per 100 mL, normal o1 mg per 100 mL), erythrocyte sedimentation rate (92 mm/h, normal o20 mm/h) and angiotensinconverting enzyme level (96 U/L, normal 9-67 U/L) mimicking that seen in sarcoidosis. Anti-nuclear antibody was normal. Joint aspiration of the R knee was performed and synovial fluid was sent for a cell count and cytology, which were unremarkable. Prednisone was then started at 2 mg/kg/day with gradual resolution of knee pain and swelling.
Peripheral blasts were noted 12 days from the onset of hypercalcemia and examination revealed significant splenomegaly. FISH analysis of the BM revealed 19% monosomy 7-positive cells. Cyclosporine and prednisone were rapidly tapered to promote a GVL effect and a subsequent BM aspirate on the twentieth hospital day revealed 490% blasts ( Figure 1 ). Our patient then underwent salvage chemotherapy with 5 days of clofarabine and cytarabine followed by a PBSC infusion. He was continued off all immunosuppression and was discharged 19 days post-transplant with no signs of GVHD.
Different mechanisms have been proposed to explain the pathophysiology of hypercalcemia of malignancy, one of the most common being direct skeletal invasion by cancer cells. Other mechanisms include osteoclast activation by humoral mediators such as PTH-related peptide (PTHrP), extrarenal vitamin D sterols or proinflammatory cytokines. [2] [3] [4] [5] [6] [7] PTHrP has been considered to be the major mediator of hypercalcemia in malignancies, especially in solid tumors. PTHrP shares similar activity with PTH and leads to hypercalcemia by decreasing urinary calcium excretion, upregulating calcitriol (1,25(OH) 2 vitamin D) production and stimulating osteoclast activity. 8 Calcitriolmediated hypercalcemia is seen in 5-15% of lymphomas, 9 but also in granulomatous diseases such as sarcoidosis. Although our patient's clinical presentation closely mimicked sarcoidosis, the 1,25(OH) 2 vitamin D level was low, making this diagnosis unlikely.
We attributed our patient's hypercalcemia to cytokinemediated osteoclast activation. He presented with significant hypercalcemia associated with focal knee swelling and elevated inflammatory markers. Serum levels of PTH, PTH-related peptide and vitamin D were normal.
Proinflammatory cytokines have been postulated to promote bone resorption by stimulating osteoclast proliferation and maturation. Such cytokines include TNF-a, IL-1, IL-2, IL-6 and prostaglandin E2. 3, 6 Unfortunately, these values were not obtained in our case due to lack of routine availability of assays for these cytokines. One proposed mechanism is that these osteotropic factors mediate osteoclast differentiation by upregulating expression of receptor activator of nuclear factor kb ligand (RANKL), a possible final common pathway for osteoclastic bone destruction. 10 The treatment of severe hypercalcemia is fourfold, namely: (1) aggressive hydration with normal saline (to maintain urine output X3 mL/kg/h), (2) furosemide therapy (2 mL/kg/dose as necessary), (3) bisphosphonates (pamidronate 0.5-1 mg/kg i.v. over 4 h), which block bone resorption by absorbance into hydroxyapatite and inhibit osteoclastic activity by inducing apoptosis and (4) calcitonin (4 U/kg s.c. every 6 h), which decreases skeletal reabsorption and promotes renal excretion of calcium. Peritoneal or hemodialysis is reserved for cases of renal failure. Monitoring for delayed secondary hypocalcemia and hypophosphatemia (both were observed in our patient) is recommended for up to 2 weeks after pamidronate administration. 1, 2 Our review of the literature revealed only five cases of hypercalcemia in pediatric AML patients, none of which were associated with relapse following BMT. [2] [3] [4] There has only been one other case in the literature of hypercalcemia associated with relapse after BMT in a 32-year-old man. 5 Our case is unique in that the clinical presentation closely mimicked that of a rheumatological process, coming close to a diagnosis of underlying sarcoidosis, and was highly responsive to steroid therapy. To our knowledge, there have been no previous reports of this proinflammatory cytokine-mediated phenomenon in either AML or leukemia relapse following BMT. 
